This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Tigecycline parenteral

Updated 2 Feb 2023 | Tetracyclines


Powder for solution for infusion containing tigecycline.

Drugs List

  • tigecycline 50mg powder for solution for infusion
  • TYGACIL 50mg powder for solution for infusion
  • Therapeutic Indications


    Complicated intra-abdominal infections: treatment
    Complicated skin and soft tissue infections


    The duration of therapy should depend on the severity, site of infection, and the patient's clinical response to therapy.

    Consideration should be given to official local guidance on the appropriate use of antibacterial agents.


    Initial dose of 100mg, followed by 50mg every 12 hours for 5 to 14 days.


    Initial dose of 100mg, followed by 50mg every 12 hours for 5 to 14 days.


    Children aged 12 to 18 years
    50mg every 12 hours for 5 to 14 days.

    Children aged 8 to 12 years
    1.2mg/kg of tigecycline every 12 hours intravenously to a maximum dose of 50mg every 12 hours for 5 to 14 days.

    Patients with Hepatic Impairment

    Severe hepatic impairment (Child Pugh C)
    Initial dose of 100mg, followed by 25mg every 12 hours. These patients must be treated with caution and their response to treatment should be monitored.


    For intravenous infusion.


    Children under 8 years
    Diabetic foot infections

    Precautions and Warnings

    Diabetes mellitus
    Drug misuse
    Peripheral vascular disease
    Positive HIV status
    Severe hepatic impairment - Child-Pugh score greater than or equal to 10

    Advise patient dizziness may affect ability to drive or operate machinery
    Consult national/regional policy on the use of anti-infectives
    Monitor coagulation values before and during treatment
    Monitor periodically for overgrowth of non-susceptible organisms
    Monitor prothrombin times closely in patients on anticoagulant therapy
    Consider pseudomembranous colitis if patient presents with diarrhoea
    May cause anaphylactic / anaphylactoid reactions
    Prolonged use may result in superinfection with non-susceptible organisms
    Risk of pancreatitis
    Discontinue if overgrowth of resistant organisms occurs
    Advise patient not to take St John's wort concurrently

    Combination antibacterial therapy should be considered in severely ill patients with complicated intra-abdominal infections secondary to clinically apparent intestinal perforation, or patients with incipient sepsis or septic shock.

    Liver injury with predominantly cholestatic pattern in patients receiving tigecycline has been reported. Some cases of hepatic failure with a fatal outcome have also been reported. Hepatic failure may occur in patients treated with tigecycline due to the underlying conditions or concomitant medications, although a possible contribution of tigecycline should be considered.

    Pregnancy and Lactation


    Tigecycline is contraindicated in pregnancy.

    The manufacturer does not recommend the use of tigecycline during pregnancy unless the clinical condition of the mother requires treatment with tigecycline.

    Tetracycline class antibiotics, administered during the last half of pregnancy, have been known to produce permanent dental defects (discolouration and enamel defects) and a delay in ossification processes in foetuses, exposed in utero. There is no adequate data from the use of tigecycline during human pregnancy, but animal studies have shown evidence of foetal harm and miscarriage. However, it is not known if the drug crosses human placenta but Briggs (2015) suggest that tigecycline would cross to the embryo/foetus due to molecular weight and prolonged half-life.


    Use tigecycline with caution in breastfeeding.

    Manufacturer recommends that a decision should be made whether to discontinue breastfeeding or discontinue treatment with tigecycline, taking into consideration the potential benefits and risk to both the mother and infant.

    It is not known whether tigecycline is excreted in human milk. Briggs (2015) suggests due to tigecycline's limited bioavailability, it would be unlikely that the infant would absorb clinically relevant levels over brief exposure. The potential of modification of infant's bowel flora or other effects on the infant cannot be ruled out.

    Side Effects

    Abdominal pain
    Acute pancreatitis
    Anaphylactoid reaction
    Cholestatic jaundice
    Dental discolouration
    Elevated amylase levels
    Hepatic failure
    Increase in blood urea nitrogen
    Increase in serum ALT/AST
    Increased partial thromboplastin time
    Inflammation (injection site)
    Liver damage
    Local pain (injection site)
    Oedema (injection site)
    Phlebitis (injection site)
    Prothrombin time increased
    Pseudomembranous colitis
    Pseudotumour cerebri
    Septic shock
    Skin reactions
    Stevens-Johnson syndrome


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: June 2019

    Reference Sources

    Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, 10th edition (2015) ed. Briggs, G., Freeman, R. Wolters Kluwer Health, Philadelphia

    Summary of Product Characteristics: Tygacil 50 mg powder for solution for infusion. Pfizer Ltd. Revised April 2019.

    NICE Evidence Services Available at: Last accessed: 06 June 2019

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.